by Sue Robbins | Jun 11, 2021 | Migraine
Read more here
by Sue Robbins | Nov 12, 2020 | Migraine
Novartis announced positive results from a phase 4 study comparing treatment with erenumab (Aimovig), a calcitonin gene-related peptide (CGRP) receptor antagonist, to topiramate in patients with episodic and chronic migraine. The randomized, double-blind,...
by Sue Robbins | Jul 30, 2020 | Migraine
Phase 3 ADVANCE trial evaluating atogepant meets primary endpoint of statistically significant reduction from baseline in mean monthly migraine days, compared to placebo, for all doses evaluated across a 12-week treatment period – Trial also...
by Sue Robbins | Jun 22, 2015 | Headache Drugs
A recent report has raised concerns that the drug topiramate, which the FDA recently approved for migraine prevention, may increase the risk of eating disorders in some teens. Jocelyn Lebow, PhD, a child and adolescent psychologist at the University of Miami Miller...